Home /
Chemotherapy – Erasmus Medical Center – Treatment Details
|
|
Description: |
Patients: This Phase II study involved 27 patients with malignant pleural mesothelioma. None of these patients had been administered prior chemotherapy.
Treatment: The treatment consisted of the chemotherapy drug, temozolomide (temodar). Toxicity: Grade 3-4 toxicities included hematologic, infection, nausea, vomiting, and arthralgia. Results: The median overall survival from the time the patient registered in the study was 8.2 months. Support: Schering-Plough International supported this study. Schering-Plough markets temodar. Correspondence: J.P. van Meerbeeck |